Fred Hutchinson Cancer Research Center
Cures Start Here
Fred Hutch's mission is the elimination of cancer and related diseases as causes of human suffering and death. The Hutch conducts research of the highest standards to improve prevention and treatment of cancer and related diseases. In fulfilling the mission of Fred Hutch: biological scientists conduct fundamental research to discover mechanisms underlying the life of normal cells and changes in these processes that cause disease; clinical research scientists develop and test new forms of diagnosis and therapy; public health scientists develop and apply new knowledge to help individuals and communities reduce the incidence and death rate from cancer and related diseases. Scientists from all fields integrate their findings and insights to foster the development and testing of new approaches.
Dr. Gary Gilliland M.D.
Fred Appelbaum M.D.
1100 Fairview Ave N P.O. Box 19024
Seattle, WA 98109 USA
Cancer, Medical Research, HIV, Healthcare, Biology, Science, Clinical, Public Health, Infectious Diseases, Immunotherapy
IRS Filing Requirement
This organization is required to file an IRS Form 990 or 990-EZ.
Add a problem overview to your profile.Update now
What are the organization's current programs, how do they measure success, and who do the programs serve?
SOURCE: Self-reported by organization
Basic science discoveries are the foundation for ultimately understanding the causes of and developing the treatments for human disease.
The Division of Basic Sciences at Fred Hutch was founded in 1981 with the goal of providing a unique and exciting environment to foster creative and ground-breaking research. The Division maintains an egalitarian philosophy that promotes stimulating and creative science. The Division's emphasis on scientific excellence, collegiality and interactivity has led to many important scientific advances. These include key discoveries related to the molecular basis of differentiation, epigenetic and genetic controls of gene transcription, mechanisms of signal transduction, regulation of the cell cycle, molecular controls over HIV and other viruses, the structural basis for RNA and DNA enzymes and regulation of developmental processes. The Division consists of ~30 laboratories that investigate the cellular and molecular mechanisms behind disease and the operations of complex systems. This fundamental understanding of how biology works leads to discoveries and better therapeutic interventions. Our scientists often take existing knowledge and link it in new ways- behind every breakthrough are basic discoveries.
From laboratory bench to bedside, the Clinical Research Division develops and analyzes new treatments for cancers and other diseases.
The Division’s research started in the late 1960s and, led by Dr. E. Donnall Thomas, our investigators achieved a major breakthrough by developing bone marrow transplantation. Thomas received the 1990 Nobel Prize in physiology or medicine for this pioneering work.
The Division is now home to more than 100 faculty members and dozens of individual labs, and our research has expanded to encompass 12 diverse areas including: Hematopoietic Cell Transplantation, Cord Blood Transplants, Immunotherapy, Gene therapy, Solid tumor biology, genetics, clinical biostatistics.
The goal of the Human Biology Division is to cultivate interdisciplinary research focused on human biology and to increase the ongoing research on solid tumor cancer and other complex human diseases.
The Human Biology Division was formed in 1998 by merging Fred Hutch’s Cancer Biology Program and the Division of Molecular Medicine with an initiative in genetics/genomics. It is structured to foster and support ongoing laboratory-based and computational research at the interface of basic, clinical, and population sciences. The Division has more than 23 faculty members with expertise in molecular and cell biology, genomics, genetics, virology, infectious disease, computational biology, pathology and clinical research.
Division researchers are using a multidisciplinary approach to achieve a better understanding, diagnosis, treatment, and prevention of human disease. The research blends fundamental, applied, and translational research that is solidly grounded in high-quality basic research into molecular mechanisms, often performed in model organisms and in vitro systems.
The close interaction of this broad collection of talented and motivated investigators provides unique opportunities for synergistic collaborations. In other institutions, such a diverse faculty would be distributed among many different departments.
Public Health Sciences
The Division of Public Health Sciences (PHS) is home to the the first National Cancer Institute-funded cancer prevention research program in the country — and important endeavor, considering that many cancers may be avoidable by changes in lifestyle. The Division was originally established within the Fred Hutch in 1975 as the Program in Epidemiology and Biostatistics. In 1983, it gained Division status coincident with the creation of the Cancer Prevention Research Program, the first NCI funded cancer prevention research unit.
Collaboration is at the heart of PHS's research endeavor. This includes the more than 140 faculty members who have appointments directly in PHS and those who have joint appointments in the Basic Sciences, Clinical Research, and Vaccine and Infectious Disease Divisions as well those at the University of Washington. Our scientists focus on finding creative and innovative ways to learn about the causes of cancer, determine how it can be detected early or prevented, establish new methodologies to design and assess biomedical research, and create computational models to address biological questions.
Vaccine and Infectious Diseases
The Vaccine and Infectious Disease Division (VIDD) was established as an institute in 2007 to facilitate and enhance the Hutch’s efforts in infectious disease prevention and vaccine development. The institute achieved division status in 2010 and currently has more than 50 faculty members. Collectively, VIDD integrates the latest in basic, computational and clinical research methods to advance the understanding of infectious disease processes.
VIDD labs utilize microbiology, biochemistry, and molecular and cellular biology methods to investigate the fundamental mechanisms underlying the pathobiology of infectious diseases. The goals of this basic science approach are to learn the key concepts of how the immune system works, how pathogens cause disease and to find ways of alleviating disease burden through preventive, diagnostic and therapeutic modalities including vaccine and drug development.
Computational biologists and biostatisticians accelerate our understanding of infectious diseases and public health via computational, statistical and mathematical modeling methods. We are home to the HIV Vaccine Trials Network (HVTN), the world’s largest clinical trials network for the development and testing of an HIV vaccine, and the Statistical Center for HIV/AIDS Research & Prevention (SCHARP).
VIDD research spans the globe, with laboratory, clinical and field sites in the Americas, Africa, Asia and Europe. The division has specific initiatives in Uganda, China and the Republic of South Africa to advance the understanding of infection-related cancers and infectious diseases that affect high-risk populations in these regions.
Where we workNew!
Five powerful questions that require reflection about what really matters - results.
SOURCE: Self-reported by organization
What is the organization aiming to accomplish?
What are the organization's key strategies for making this happen?
What are the organization's capabilities for doing this?
How will they know if they are making progress?
What have and haven't they accomplished so far?
Fred Hutchinson Cancer Research Center works to eliminate cancer and related diseases as causes of human suffering and death.
To achieve our mission, we conduct fundamental, translational and clinical research that will lead to better cancer prevention, diagnosis and treatment. Recent scientific breakthroughs have brought us to a critical point in the fight against cancer and other diseases. We believe that curative therapies for most if not all cancers can be developed by 2025.
In addition to cancer, we research HIV and other life-threatening infections and diseases. We are home to one of the world's largest HIV research units and serve as the hub of the HIV Vaccine Trials Network, a global effort to develop and test a successful HIV vaccine.
Our researchers, including three Nobel laureates, bring a relentless pursuit of health, knowledge and hope to their work. They are discovering new ways to prevent cancer; to detect cancer earlier, when cure rates are highest; and to develop effective treatments with fewer side effects.
Fred Hutch scientists conduct fundamental research on cells and changes in their processes that cause disease, develop and test new types of diagnostics and treatments, and develop and apply new knowledge that helps individuals and communities reduce the incidence and impact of cancer and related diseases.
Fred Hutch's scientific priorities are strategically focused on five high-impact areas of cancer and cancer-related disease research: transplant and immunotherapy; cancer etiology, prevention and outcomes; vaccine development and viral cancers; the molecular basis of cancer; and tumor-specific translational research. Fred Hutch is an internationally recognized leader in each of these fields, with deep expertise in cancer prevention, and preclinical and clinical application of new treatments. Our Basic Sciences Division is unparalleled and renders us unique among cancer centers.
In addition, Fred Hutch drives collaborative research through Integrated Research Centers (IRCs) that catalyze high-impact, innovative research through cross-divisional collaboration, focusing on cutting-edge, competitive areas that leverage unique Hutch resources and expertise. Recently, Fred Hutch launched an Immunotherapy IRC and a Pathogen-Associated Malignancies IRC, two areas poised for significant breakthroughs.
Through our pioneering work in bone marrow transplantation, Fred Hutch became the first research institution to demonstrate the body's ability to harness the immune system. Since that discovery, we have continued to advance the burgeoning field of immunotherapy for cancer and translate these insights to related disciplines. Our Vaccine and Infectious Disease Division, for example, grew out of our experience in bone marrow transplantation and research on the infectious complications that can occur after transplant. Today, Fred Hutch is the only cancer institute in the United States dedicated to eliminating virus-associated malignancies through vaccine development, which we anticipate will have a significant impact on the 20 percent of cancers that have an infectious cause.
To seamlessly continue research and care, Fred Hutch works to grow and diversify funding from industry partners and individuals. We are accelerating our commercialization impact by increasing the speed and scale with which we bring our specialized knowledge and technology to commercial markets so that every patient can have access to lifesaving cures. We plan to grow and diversify philanthropic support, and we welcome investment from individual donors who are passionate about delivering the cancer care of tomorrow. We will continue to work with government agencies, leaders and policymakers to maintain and grow support for research funding.
Our groundbreaking discoveries began in the 1970s with Dr. E. Donnall Thomas' pioneering work in bone marrow transplantation, which earned him the 1990 Nobel Prize in physiology or medicine. More than 1 million bone marrow transplants have since been performed around the world. Fred Hutch researchers have continued to achieve leading-edge breakthroughs, including developing immunotherapies that use the body's immune system to defeat cancer and deepening the understanding of human biology.
Today, Fred Hutch is home to five scientific divisions, two Integrated Research Centers, and more than 3,000 staff who work to eliminate cancer and related diseases. Our more than 200 faculty study over 30 diseases through the lenses of fundamental research, prevention, early detection, treatment and survivorship.
Our roster of internationally acclaimed scientists includes three Nobel laureates, a MacArthur Fellow, ten members of the National Academy of Sciences, ten members of the Institute of Medicine, eight members of the American Academy of Arts and Sciences, 14 members of the American Association for the Advancement of Science, and nine current and former Howard Hughes Medical Institute investigators. Our research is leading to discoveries, translating discoveries into cures and transforming the lives of millions.
Our 15-acre Seattle campus includes state-of-the-art laboratories and inclusive shared resources, which are core facilities that provide services and access to specialized equipment available to all faculty. We strive to ensure that every Fred Hutch laboratory has access to the latest technology and can capitalize on our world-class infrastructure.
We also collaborate with scientists and clinicians from leading local academic and research institutions. In 1998, Fred Hutch joined UW Medicine and Seattle Children's to form Seattle Cancer Care Alliance, one of the top-five cancer treatment centers in the U.S. The Fred Hutch/University of Washington Cancer Consortium was formed in 2002 to enhance and accelerate cancer research at Fred Hutch, UW Medicine and Seattle Children's by bringing together 400 faculty with cancer-research interests in the basic, clinical and public health sciences.
In addition to local collaborations, Fred Hutch works with national and international partners to address the global impact of cancer, which is projected to grow by nearly 70 percent by 2030. Our research and clinical trials span the globe, touching lives in more than 70 countries. Fred Hutch has formed a unique partnership with the Uganda Cancer Institute, the first comprehensive cancer center jointly built by U.S. and African cancer institutions in sub-Saharan Africa. Fred Hutch's international reach also extends to China, where our China Initiative aims to share scientific data, statistical analysis methods and clinical research developments through research partnerships with organizations such as the Chinese Center for Disease Control and Prevention.
Patient outcomes are the most important marker of progress at Fred Hutch, and we strive every day to deliver curative therapies that will benefit patients around the world. Translational research — the process of scaling fundamental research into medical practice — is the cornerstone of our work.
Clinical trials are critical to finding new ways to treat diseases and save lives. Each year, hundreds of clinical trials are underway at Fred Hutch, with more waiting for funding. These trials give patients access to the newest treatments and help our investigators develop effective therapies faster. Our progress is marked by the expansion of these trials to bring novel therapies to thousands of patients.
Our research is having an increasingly significant impact on the number of people who are affected by cancer, as we learn how to better prevent, diagnose and treat it. For example, when the Hutch-based Women's Health Initiative found that combined hormone therapy dramatically increases breast cancer risk, millions of women stopped taking the drugs, preventing up to 20,000 cases of breast cancer in the U.S. each year.
Scientific publications are vital to disseminating the latest research discoveries to other cancer centers, universities and health care facilities. In 2016, Fred Hutch produced 1,356 publications, averaging six publications per faculty member. Fred Hutch papers are cited 2.5 times more often than average. The insights shared through these articles are catalyzing further discoveries across the spectrum of biomedical research.
Our pioneering work in bone marrow and stem cell transplantation in the 1970s has resulted in more than 1 million bone marrow transplants being performed worldwide. It also demonstrated the potential of the immune system to wipe out cancer. Today, we continue to research and refine these and related transplantation techniques. For example, we are evaluating transplants conducted with umbilical cord blood cells, which can overcome limitations associated with bone marrow transplantation, including the requirement for a close donor match.
We continue to harness the power of the immune system through a world-leading immunotherapy program. For example, Fred Hutch scientists were the first to show that a patient's own infection-fighting T cells could, as the sole therapy, put aggressive melanoma in long-term remission through immunotherapy.
Hutch research laid the groundwork for the HPV vaccine, which prevents cervical cancer and is poised to save millions of lives worldwide. As many as one in five cancer cases around the world is linked to infections such as HPV, short for human papillomavirus, and our research teams are developing novel ways to treat and prevent them.
In 2016, Fred Hutch opened the Bezos Family Immunotherapy Clinic, a first-of-its-kind resource that has more than doubled our capacity to serve patients with leukemias and other cancers, including certain solid tumors, in our immunotherapy clinical trials. Many of the patients seen at the new clinic, including the very first study participant, have gone into complete remission after participating in one of the clinical trials taking place there.
Fred Hutch researchers are also delivering targeted therapies to treat solid tumors via our partnership with Seattle Translational Tumor Research (STTR), a multidisciplinary and multi-organizational effort to translate laboratory science into the most precise treatment options for patients with solid tumors. STTR builds on ongoing research on solid tumor cancers that is being performed in basic science, human biology, clinical research and public health science to translate this focused commitment to advance treatment for solid tumors.
The Hutchinson Outcomes Research Center (HICOR) is a collaborative research institute at Fred Hutch that facilitates data sharing from providers and patients at Fred Hutch and numerous research institutions to guide improvements in cancer care. HICOR enables data-driven decisions on care consistency and cost-effectiveness that shape program design, best practices and policies that seek to reduce the economic burden of cancer treatment while improving outcomes for patients.
We at Fred Hutch will continue to build on and extend our diverse research expertise to deliver the cancer prevention, detection and treatment of tomorrow. We are working toward nothing less than cures.
Fred Hutchinson Cancer Research Center
Need more info on this nonprofit?
The people, governance practices, and partners that make the organization tick.
as of 11/16/2018
Mr. Matthew McIlwain
Madrona Venture Group
Washington Real Estate Holdings
JH Kelly Holdings LLC
Fenwick & West LLP
Herbold Group LLC
NanoString Technologies Inc.
Sahsen Ventures LLC
Former Washington Governor
SOURCE: Self-reported by organization
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section, which enables organizations and donors to transparently share information about essential board leadership practices.SOURCE: Self-reported by organization
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations?
Has the board conducted a formal, written assessment of the chief executive within the past year?
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year?
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership?
Has the board conducted a formal, written self-assessment of its performance within the past three years?
In order to support nonprofits and gain valuable insight for the sector, GuideStar worked with D5—a five-year initiative to advance diversity, equity, and inclusion in philanthropy—in creating a questionnaire. This section is a voluntary questionnaire that empowers organizations to share information on the demographics of who works in and leads organizations. To protect the identity of individuals, we do not display sexual orientation or disability information for organizations with fewer than 15 staff. Any values displayed in this section are percentages of the total number of individuals in each category (e.g. 20% of all Board members for X organization are female).SOURCE: Self-reported by organization
This organization reports that it does not collect this information for Board Members.
This organization reports that it does not collect this information for Board Members, Senior Staff, Full-Time Staff and Part-Time Staff.